...
首页> 外文期刊>Modern Pathology >Gastric Dysplasia-Like Epithelial Atypia Associated with Chemoradiotherapy for Esophageal Cancer: A Clinicopathologic and Immunohistochemical Study of 15 Cases
【24h】

Gastric Dysplasia-Like Epithelial Atypia Associated with Chemoradiotherapy for Esophageal Cancer: A Clinicopathologic and Immunohistochemical Study of 15 Cases

机译:胃异型增生样上皮异型性伴食管癌放化疗:15例临床病理和免疫组织化学研究

获取原文
           

摘要

Preoperative chemotherapy combined with radiotherapy (chemrad) is a common type of neoadjuvant treatment for esophageal adenocarcinoma or squamous cell carcinoma. The purpose of this study was to describe the clinical, histologic, proliferative (MIB-1), and oncogenetic (p53) features of 15 patients with gastric dysplasia-like epithelial atypical changes associated with preoperative chemrad for esophageal cancer. Two of these cases were initially misinterpreted as dysplasia, which led to partial gastrectomy. The findings were compared with 12 age- and sex-matched patients with known gastric dysplasia. Cases with gastric dysplasia-like epithelial atypia were significantly associated with a flat gross appearance, a patchy distribution, foveolar and gland involvement, surface maturation, an open nuclear chromatin pattern with prominent nucleoli, retention of nuclear polarity, mitoses confined to the pits, lack of atypical mitoses, cytoplasmic hypereosinophila and/or vacuolization, a lack of association with intestinal metaplasia, and finally, irregular glandular microcystic change, in comparison to the dysplasia controls. Furthermore, the study cases showed MIB-1 positivity restricted to the deep foveolar epithelium and an absence of p53 staining in 14 of 15 cases, in contrast to the dysplasia controls, in which MIB-1 stained both the deep and superficial foveolar epithelium and surface epithelium, and p53 was positive in all cases (100%). In summary, a number of histologic and immunohistochemical features may distinguish gastric dysplasia-like epithelial atypia associated with chemrad for esophageal cancer from true dysplasia. Pathologists should be aware of this entity and its histologic and immunohistochemical features to avoid misinterpretation and prevent unnecessary treatment.
机译:术前化疗联合放疗(chemrad)是食管腺癌或鳞状细胞癌的新辅助治疗的一种常见类型。这项研究的目的是描述15例与食管癌术前chemrad相关的胃异型增生样上皮非典型性改变的患者的临床,组织学,增殖性(MIB-1)和致癌性(p53)特征。这些案例中有两个最初被误解为发育不良,从而导致部分胃切除术。将研究结果与12名年龄和性别相匹配的已知胃发育不良的患者进行了比较。胃异型增生样上皮异型症的病例与平坦的肉眼外观,斑块状分布,小叶和腺体受累,表面成熟,核染色质呈核仁开放型核仁突出,核极性保留,有丝分裂仅限于凹坑,缺乏明显相关与不典型增生的对照相比,非典型的有丝分裂,胞浆性嗜酸性粒细胞增多和/或空泡化,缺乏与肠化生的关系以及最后不规则的腺体微囊性改变。此外,与非典型增生对照组相比,MIB-1染色深部和浅表的腓骨上皮和表面,在研究病例中,MIB-1阳性仅局限在深小叶上皮和15例中的14例中没有p53染色上皮和p53在所有情况下均为阳性(100%)。总之,许多组织学和免疫组织化学特征可将与chemrad合并食管癌的chemad相关的胃异型增生样上皮异型与真正异型增生区分开。病理学家应了解该实体及其组织学和免疫组化特征,以避免误解并防止不必要的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号